

Patricia R Freeman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4669440/publications.pdf>

Version: 2024-02-01

67
papers

1,511
citations

331670

21
h-index

330143

37
g-index

67
all docs

67
docs citations

67
times ranked

1575
citing authors

#	ARTICLE	IF	CITATIONS
1	Eliciting Willingness to Pay Without Bias: Evidence from a Field Experiment. <i>Economic Journal</i> , 2008, 118, 114-137.	3.6	273
2	Hypothetical versus real willingness to pay in the health care sector: results from a field experiment. <i>Journal of Health Economics</i> , 2001, 20, 441-457.	2.7	170
3	Association of Naloxone Coprescription Laws With Naloxone Prescription Dispensing in the United States. <i>JAMA Network Open</i> , 2019, 2, e196215.	5.9	73
4	The changing landscape of naloxone availability in the United States, 2011 – 2017. <i>Drug and Alcohol Dependence</i> , 2018, 191, 361-364.	3.2	72
5	Pharmacists'™ role in opioid overdose: Kentucky pharmacists'™ willingness to participate in naloxone dispensing. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, S28-S33.	1.5	69
6	Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky. <i>International Journal of Drug Policy</i> , 2020, 85, 102701.	3.3	64
7	Implementation of personalized medicine services in community pharmacies: Perceptions of independent community pharmacists. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2014, 54, 510-517.	1.5	54
8	Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings. <i>Drug and Alcohol Dependence</i> , 2018, 184, 26-32.	3.2	50
9	The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108325.	3.2	50
10	The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108335.	3.2	50
11	Assessment of the Relationship Between Measures of Disease Severity, Quality of Life, and Willingness to Pay in Asthma. <i>Pharmacoeconomics</i> , 2002, 20, 257-265.	3.3	45
12	When Prescribing Isn't Enough – Pharmacy-Level Barriers to Buprenorphine Access. <i>New England Journal of Medicine</i> , 2020, 383, 703-705.	27.0	41
13	Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 754-760.	3.0	40
14	Community engagement to implement evidence-based practices in the HEALing communities study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108326.	3.2	38
15	Trends and Patterns of Opioid Analgesic Prescribing: Regional and Rural-Urban Variations in Kentucky From 2012 to 2015. <i>Journal of Rural Health</i> , 2019, 35, 97-107.	2.9	36
16	Trends in Gabapentin Prescribing in a Commercially Insured U.S. Adult Population, 2009-2016. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 246-252.	0.9	33
17	Patterns and predictors of chronic opioid use in older adults: A retrospective cohort study. <i>PLoS ONE</i> , 2019, 14, e0210341.	2.5	28
18	Polyamines and Epidermal Growth Factor in Monocrotaline-induced Pulmonary Hypertension. <i>The American Review of Respiratory Disease</i> , 1989, 140, 1463-1466.	2.9	26

#	ARTICLE	IF	CITATIONS
19	Independent community pharmacist interest in participating in community pharmacy research networks. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2011, 51, 727-738.	1.5	24
20	Development and delivery of a pharmacist training program to increase naloxone access in Kentucky. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, S118-S122.	1.5	24
21	Pharmacists'™ role in harm reduction: a survey assessment of Kentucky community pharmacists'™ willingness to participate in syringe/needle exchange. <i>Harm Reduction Journal</i> , 2018, 15, 4.	3.2	23
22	Statin Use and Gastrointestinal Hemorrhage: A Large Retrospective Cohort Study. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 65-74.	2.2	17
23	Prescription drug monitoring program utilization in Kentucky community pharmacies. <i>Pharmacy Practice</i> , 2015, 13, 540.	1.5	17
24	Communication between pharmacists and primary care physicians in the midst of a U.S. opioid crisis. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 974-985.	3.0	14
25	Rapid Expansion of the Opioid Ecosystem: National Implications for Prescriber-Pharmacist Communication. <i>American Journal of Preventive Medicine</i> , 2018, 55, 656-661.	3.0	13
26	Co-prescription network reveals social dynamics of opioid doctor shopping. <i>PLoS ONE</i> , 2019, 14, e0223849.	2.5	12
27	Association between state Medicaid expansion status and naloxone prescription dispensing. <i>Health Services Research</i> , 2020, 55, 239-248.	2.0	12
28	Epidermal Growth Factor Augments Reactivity to Angiotensin II in the Rat Pulmonary Circulation. <i>The American Review of Respiratory Disease</i> , 1989, 140, 821-824.	2.9	11
29	Immunization Training: Right or Privilege?. <i>American Journal of Pharmaceutical Education</i> , 2012, 76, 57.	2.1	11
30	Trends in Drug Overdose Mortality Rates in Kentucky, 2019-2020. <i>JAMA Network Open</i> , 2021, 4, e2116391.	5.9	11
31	“Doctor and pharmacy shopping”: A fading signal for prescription opioid use monitoring?. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108618.	3.2	10
32	Predicting substance use disorder using long-term attention deficit hyperactivity disorder medication records in Truven. <i>Health Informatics Journal</i> , 2020, 26, 787-802.	2.1	8
33	Primary care clinician and community pharmacist perceptions of deprescribing. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1686-1689.	2.6	8
34	A qualitative study on pharmacy policies toward over-the-counter syringe sales in a rural epicenter of US drug-related epidemics. <i>Harm Reduction Journal</i> , 2022, 19, 1.	3.2	8
35	Anakinra Shows Promise for Treating Patients With Rheumatoid Arthritis. <i>Journal of the American Pharmacists Association</i> , 2002, 42, 660-662.	0.5	7
36	Changing Trends in Drug Overdose Mortality in Kentucky: An Examination of Race and Ethnicity, Age, and Contributing Drugs, 2016-2020. <i>Public Health Reports</i> , 2023, 138, 131-139.	2.5	7

#	ARTICLE	IF	CITATIONS
37	Perception of prescription drug monitoring programs as a prevention tool in primary medical care. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1306-1308.	3.0	6
38	Biotechnology Update: Pharmacogenetics and Pharmacogenomics: Using Genetic Information to Guide Therapeutic Decision Making. <i>Journal of the American Pharmacists Association</i> , 2001, 41, 475-476.	0.5	5
39	Teriparatide: A Novel Agent That Builds New Bone. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2003, 43, 535-537.	1.5	5
40	Regulating gabapentin as a drug of abuse: A survey study of Kentucky community pharmacists. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2019, 59, 379-382.	1.5	5
41	New means, new measures: assessing prescription drug-seeking indicators over 10 years of the opioid epidemic. <i>Addiction</i> , 2022, 117, 195-204.	3.3	4
42	Biotechnology Update: Pharmacogenomics: Opening New Vistas in Pharmacotherapy. <i>Journal of the American Pharmacists Association</i> , 2001, 41, 629-630.	0.5	3
43	Pseudoephedrine Sales and Seizures of Clandestine Methamphetamine Laboratories in Kentucky. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1524.	7.4	3
44	Predicting Substance Use Disorder in ADHD Patients using Long-Short Term Memory Model. , 2018, 2018, 49-50.		3
45	Appalachian disparities in tobacco cessation treatment utilization in Medicaid. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2020, 15, 5.	2.2	3
46	Variation in Abuse-Deterrent Formulation Opioid Prescribing in California, Florida, and Kentucky in 2018. <i>Journal of Rural Health</i> , 2021, 37, 23-28.	2.9	3
47	Broadband internet subscription rates and opioid prescribing via telemedicine during the COVID-19 pandemic. <i>Journal of Rural Health</i> , 2022, 38, 900-907.	2.9	3
48	Abuse-Deterrent Opioids: A Survey of Physician Beliefs, Behaviors, and Psychology. <i>Pain and Therapy</i> , 2022, 11, 133-151.	3.2	3
49	Changes in transmucosal buprenorphine utilization for opioid use disorder treatment during the COVID-19 pandemic in Kentucky. <i>Journal of Rural Health</i> , 2023, 39, 186-196.	2.9	3
50	PHP93 Impact of Prescription Monitoring Programs on Pharmacists' Controlled Substance Dispensing Behavior. <i>Value in Health</i> , 2012, 15, A29-A30.	0.3	2
51	Law Enforcement Perceptions of a Prescription Drug Monitoring Programme. <i>International Journal of Police Science and Management</i> , 2014, 16, 288-296.	1.3	2
52	Kentucky pharmacists's™ opinions of the potential reclassification of pseudoephedrine as a legend drug. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2014, 54, 397-405.	1.5	2
53	Attitudes toward pharmacy-based HCV/HIV testing among people who use drugs in rural Kentucky. <i>Journal of Rural Health</i> , 2022, 38, 93-99.	2.9	2
54	Monoclonal Antibody Approved for Treatment of Crohn's Disease. <i>Journal of the American Pharmacists Association</i> , 1998, 38, 770-772.	0.5	1

#	ARTICLE	IF	CITATIONS
55	Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012–2017. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107606.	3.2	1
56	Obstetrician/Gynecologist Perception of Prescription Drug Monitoring Program Effectiveness [15]. <i>Obstetrics and Gynecology</i> , 2019, 133, 99S-99S.	2.4	1
57	Letter to the Editor regarding: Medicaid prescription limits and their implications for naloxone accessibility (by Roberts et al., 2021). <i>Drug and Alcohol Dependence</i> , 2021, 226, 108888.	3.2	1
58	Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States. <i>Pain Physician</i> , 2021, 24, E249-E256.	0.4	1
59	Topical Peptide Growth Factors, Wound Repair. <i>American Pharmacy</i> , 1993, 33, 18-19.	0.2	0
60	DR2 The Relationship Between Pseudoephedrine Sales and Clandestine Methamphetamine Labs. <i>Value in Health</i> , 2012, 15, A6-A7.	0.3	0
61	PMH82 Do Sales of Pseudoephedrine Predict Methamphetamine-Related Hospitalizations?. <i>Value in Health</i> , 2012, 15, A96-A97.	0.3	0
62	Kentucky Physician Opinions Of The Potential Reclassification Of Pseudoephedrine As A Legend Drug. <i>Value in Health</i> , 2013, 16, A249.	0.3	0
63	Community Pharmacist Characteristics Associated With Use Of A Prescription Drug Monitoring Program. <i>Value in Health</i> , 2014, 17, A15.	0.3	0
64	University–pharmacy partnerships for COVID-19. <i>Science</i> , 2020, 369, 1441-1441.	12.6	0
65	Characterization of gabapentin use in Kentucky after reclassification as a Schedule V controlled substance. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, 61, e86-e92.	1.5	0
66	Rural–urban differences in hospitalizations for opioid use–associated infective endocarditis in Kentucky, 2016–2019. <i>Journal of Rural Health</i> , 2021, , .	2.9	0
67	Predictors of chronic opioid therapy in Medicaid beneficiaries with HIV who initiated antiretroviral therapy. <i>Scientific Reports</i> , 2021, 11, 15503.	3.3	0